Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety, efficacy and pharmacokinetics of peginterferon alpha2a (40 kd) in children with chronic hepatitis C.

Journal of pediatric gastroenterology and nutrition - 1 Oct 2006

Schwarz Kathleen B, Mohan Parvathi, Narkewicz Michael R, Molleston Jean Pappas, Nash S Russell, Hu Sylvia, Wang Ka, Gries Jean Michel

Abstract excerpt

Chronic hepatitis C virus (HCV) infection in children is a problem affecting thousands of children worldwide. Although standard interferon (INF) has better efficacy in pediatric patients than in adults, results in children with genotype 1 are poor; response rates to combination treatment with standard INF and ribavirin are better but the treatment requires thrice-weekly injections. The improved antiviral efficacy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Administration Schedule
Share to Hepatitis C, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Injections, Subcutaneous

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Pilot Projects

Share to Polyethylene Glycols

Share to Viral Load

Source

Identifiers

PMID: 17033526
DOI: 10.1097/01.mpg.0000235974.67496.e6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety, efficacy and pharmacokinetics of peginterferon alpha2a (40 kd) in children with chronic hepatitis C.PMID 17033526Read ↗

Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C.Semantic proximity Read ↗

High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin.Semantic proximity Read ↗

Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.Semantic proximity Read ↗

Elbasvir/grazoprevir in children aged 3-18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling study.Semantic proximity Read ↗

Treatment for chronic hepatitis C in children: a review.Semantic proximity Read ↗

Pharmacokinetic evaluation of sofosbuvir/velpatasvir for the treatment of Chronic Hepatitis C in pediatrics aged 3 and older.Semantic proximity Read ↗

Meeting the WHO hepatitis C virus elimination goal: Review of treatment in paediatrics.Semantic proximity Read ↗

Population Pharmacokinetic Analysis of Glecaprevir and Pibrentasvir in Pediatric Patients ≥ 3 to < 18 Years of Age with Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection.Semantic proximity Read ↗

Management strategies for hepatitis C virus infection in children.Semantic proximity Read ↗

Hepatitis C in the pediatric population: transmission, natural history, treatment and liver transplantation.Semantic proximity Read ↗

Hepatitis C virus in infants and children.Semantic proximity Read ↗

The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.